Nucleai raised €5.8M in a Series A round in Jul 2020. The company is based in Tel Aviv, Israel. Investors in the round: Debiopharm Innovation Fund. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
